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Abstract: 6 
Objectives/Hypothesis 7 
The goal of this study was to evaluate independent risk factors for long-term epistaxis 8 
recurrences and their severity. 9 
Study design 10 
Individual retrospective cohort study - 2b level of evidence. 11 
Methods  12 
The medical information of 603 emergency epistaxis patients was acquired during a 13 
former study. This cohort has been contacted six years later by conventional mail 14 
and asked to answer a specific paper-questionnaire. The following parameters were 15 
evaluated: Recurrent epistaxis episodes, need for a surgical intervention in order to 16 
stop the recurrent bleeding, patient’s history for hypertension and diabetes, intake of 17 
hemostasis impairing medication now and in the past. 18 
Results 19 
One hundred and six (106) patients were included in the study (35.8% response 20 
rate). The mean observation period was 76.58 months. Almost half of the patients 21 
(41.5%=44/106) reported at least one recurrent epistaxis episode. Patients with 22 
exposure to VKA (vitamin K antagonists) showed significantly more frequently a 23 
recurrent epistaxis episode. The binary logistic regression confirmed the intake of 24 
VKA as an independent and significant risk factor with an odds ratio of 11.6. Every 25 
single patient who had to undergo a surgical intervention in order to stop a recurrent 26 
bleeding stated ASA (Acetylsalicylic Acid) intake. 27 
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Conclusion 28 
We provide evidence that the intake of a vitamin K antagonist is an independent 29 
long-term risk factor for recurrent epistaxis episodes. 30 
The intake of ASA is a risk factor for the severity of recurrent epistaxis with the 31 
increased need for a surgical intervention not only in a short- but also in a long-term 32 
perspective. 33 
 34 
 35 
 36 
 37 
 38 
 39 
 40 
 41 
 42 
 43 
 44 
 45 
 46 
 47 
 48 
 49 
 50 
 51 
 52 
 53 
3 
 
 54 
 55 
 56 
Key-Words: 57 
Epistaxis, Nose bleed, Recurrence, Risk Factors, Prognosis, Prevalence, Warfarin, 58 
ASA, Aspirin, Acetylsalicylic Acid 59 
 60 
Level of Evidence: 61 
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Introduction:  83 
Epistaxis is a leading cause for admission to the otorhinolaryngologic emergency 84 
room. The majority of the population will suffer a nosebleed at some point in their life. 85 
Epidemiologic surveys showed an adult life prevalence of 60 percent for an epistaxis 86 
episode. Only every tenth case seeks medical attention.1 87 
Besides the idiopathic episodes, where the cause remains unclear, the etiology can 88 
either be local or systemic. Concerning systemic etiologies, one must be aware of 89 
iatrogenic influences on the hematologic equilibrium through medication exposure. 90 
First and foremost important hemostasis impairing medications like vitamin K 91 
antagonists or antiplatelet drugs interfere with this system. Hemorrhagic side effects 92 
of oral anticoagulation or antiplatelet drugs seem intuitively apparent regarding their 93 
pharmacological characteristics and goals.2 Patients on such medication walk a 94 
tightrope between reducing the risk for thrombotic events and the inevitable risk of 95 
bleeding. 96 
On a daily basis, we are often confronted with epistaxis patients’ concerns about their 97 
course of any following bleeding episodes in the future, not only inquiring about the 98 
moment but also the following years. 99 
It is important to be able to define independent risk factors and evaluate their 100 
presence in order to give the patient an adequate and customized prediction. For this 101 
purpose, the exact acquirement of a patient’s history is once again of utmost 102 
importance. 103 
Several epistaxis risk factors have been investigated and discussed controversially 104 
for many years, i.e. physical and chemical irritation, temperature and humidity, 105 
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hypertension, septal pathologies and inflammatory conditions. Some proposed 106 
factors were able to maintain their position and others were pushed into the 107 
background. In recent years, anticoagulative and antiaggregative medication, 108 
traumatic injury, alcohol consumption, hematologic disorders and long lasting 109 
hypertension/arteriosclerosis could maintain their position in being relevant risks for 110 
nasal bleeding. 5,6,7,8,9 111 
However, the impact of independent risk factors after an epistaxis episode in a long-112 
term perspective is largely unknown. 113 
Based on a study of our clinic that investigated risk factors within epistaxis patients 114 
presenting at the ENT (Ear, Nose and Throat) emergency3, we designed a long-term 115 
follow-up survey study. 116 
The goal of this study was to evaluate, whether certain independent factors could 117 
help to predict any recurrences and their severity on the basis of long-term survey 118 
data. 119 
 120 
 121 
122 
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Materials and Methods: 123 
This investigation was designed as a cohort survey study at the University Hospital of 124 
Zurich. During a former study we systematically collected medical information of 603 125 
emergency epistaxis patients who have been seen and treated at the unit (including 126 
in hospital therapy and outpatient treatment) of our tertiary ENT department.3 The 127 
treating physician obtained and stored the data electronically at a pre-programmed 128 
form within the clinical information system. The data of this initial cohort was 129 
prospectively obtained in the period from March 29, 2007 to April first, 2008. 130 
In our clinical information system, 35 patients from the initial cohort have been 131 
registered as deceased in the meantime. The remaining patients of the cohort have 132 
been contacted by conventional mail in April 2014 and asked to answer a specific, 133 
psychologically elaborated, but not validated, paper-questionnaire (Table I). The 134 
paper-questionnaire had a multiple-choice design and could be sent back to us by 135 
mail without any charges. However, participation in the survey was voluntary and 136 
without any compensation. 137 
The data of this survey cohort was also part of a second study estimating the long-138 
term outcome and satisfaction after the treatment at our ENT department (manuscript 139 
submitted). 140 
We directed our attention particularly on following parameters of the patient’s medical 141 
history: Any recurrent epistaxis episodes, the need for a surgical intervention in order 142 
to stop the recurrent bleeding, the patient’s history of hypertension and diabetes, and 143 
the intake of hemostasis impairing medication now and in the past. 144 
The patient was asked if he or she could recall the initial nosebleed and its treatment. 145 
Additionally, he or she was asked whether the initial treatment was performed under 146 
general or local anesthesia. The collected data from the paper survey was 147 
transferred into a digital format, which then was imported into the statistics software. 148 
7 
 
We matched these survey answers with the digitally documented protocols in our 149 
clinical information system and excluded patients with incongruent data.  150 
The occurrence of a recurrent epistaxis episode during the long-term observation and 151 
the surgical intervention at a recurrent episode were defined as primary endpoints. 152 
The statistical analyses were performed by the Statistical Package for the Social 153 
Sciences software (SPSS) version 22.0.0.1 (IBM Corp., Armonk, NY, USA).  154 
We performed descriptive statistical analyses and cross-tabulating Pearson Chi-155 
Square tests with asymptotic two-sided significances to evaluate differences in the 156 
captured characteristics between the patients group with or without recurrent 157 
epistaxis. Binary logistic regression was conducted with recurrent bleeding as 158 
dependent variable and following factors as covariates: Sex, age, intake of 159 
hemostasis impairing medication: ASA (Acetylsalicylic Acid), Marcoumar® 160 
(Phenprocoumon), Plavix® (Clopidogrel), other; patient’s history of hypertension and 161 
diabetes. We performed the Hosmer-Lemeshow test, which is an evaluated test to 162 
determine the goodness of fit of the logistic regression model. Confidential interval for 163 
the exponentiation of the B coefficient - Hazard Ratio - was defined as 95%. Results 164 
were considered statistically significant at the p-level <0.05. 165 
The study was conducted in accordance to the latest version of the Helsinki 166 
declarations and with the permission of the ethical committee of the canton of Zurich 167 
(KEK-ZH-Nr.: 2013-0519, ClinicalTrials.gov-Identifier: NCT02127554).  168 
 169 
 170 
 171 
172 
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Results: 173 
A total of 568 conventional mails have been sent to patients from the initial cohort. 174 
205 mails were returned by the postal service, due to impossible delivery. 28 mails 175 
returned with a death notice by the relatives or carer of the patient. 176 
120 patients returned the filled in questionnaire by mail (120/335=35.8%). These 120 177 
patients answering the request originate from the initial cohort. Their data will be 178 
labeled as “survey cohort”. Seven patients had to be excluded from the survey cohort 179 
because they did not remember the initial treatment. Four patients did remember the 180 
treatment incongruently to our clinical information system. These eleven patients 181 
were excluded from the study to eliminate other potentially incorrectly remembered 182 
data. Additionally, one patient did not answer the survey-question about any 183 
recurrent epistaxis episodes and two patients did not answer the survey-question 184 
about the actual use of hemostasis impairing medication. Therefore, 106 patients 185 
were analysed. 186 
The survey cohort consisted of 68.9% (73) male and 31.1% (33) female patients. 187 
This imbalance did not show a significant difference concerning the primary endpoint 188 
of a recurrence. The mean interval between the initial cohort and the survey cohort 189 
was 76.58 months (SD 4.0 [71 – 84 Mt]). The initial cohort showed the following 190 
distribution of hemostasis impairing medication intake: 46.2% (49/106) none, 34.9% 191 
(37/106) ASA only, 10.4% (11/106) VKA, 7.5% (8/106) combined antiplatelet therapy 192 
of ASA and Clopidogrel, 0.9% (1/106) Clopidogrel only. 193 
The survey cohort showed following distribution of hemostasis impairing medication 194 
intake: 49.1% (52/106) none, 36.8% (39/106) ASA, 10.4% (11/106) VKA, 0.9% 195 
(1/106) combined therapy of ASA and VKA, 0.9% (1/106) antiplatelet therapy with 196 
Clopidogrel, 1.9% (2/106) other. The shift of types of treatment is depicted in Figure 197 
1. Regarding the overall ASA shift in single cases reveals that 17 patients of initially 198 
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45 (37.8%) discontinued ASA intake between the initial and the survey time point. In 199 
contrast did eleven patients start to take ASA. Of those eleven patients did eight 200 
individuals declare no exposure to any antithrombotic medication at the initial cohort, 201 
and three individuals declared exposure to a VKA. The need for an adaptation of the 202 
VKA therapy or application of Vitamin K in the initial cohort has been published 203 
previously14. 204 
Regarding the overall VKA shift in single cases reveals that three patients of initially 205 
eleven (27.3%) discontinued VKA intake between the initial cohort and the survey 206 
cohort. In contrast did four patients start to take VKA. Of those four patients did three 207 
individuals declare exposure to ASA only at the initial cohort, and one individual 208 
declared exposure to the combination of ASA and Clopidogrel. 209 
 210 
41.5% (44/106) reported a recurrent epistaxis episode on either side of the nose. 211 
Patients that declared intake of a VKA at the survey showed significantly more 212 
frequently a recurrent epistaxis episode (p = 0.002). 83.3% (10/12) of patients with 213 
exposure to VKA suffered from a recurrent episode, while 16.7% (2/12) did not 214 
(Table 2). 215 
The binary logistic regression confirmed the intake of VKA as an independent and 216 
significant risk factor for a recurrent epistaxis episode with an odds ratio of 11.6 217 
(p=0.007) (Table 3). Goodness of fit was confirmed by the Hosmer and Lemeshow 218 
test (p = 0.882, Chi2 = 3.710). 219 
No further covariate, including any other hemostasis impairing medication, showed 220 
significance as an independent risk factor for a recurrent epistaxis episode. 221 
19 of the 44 patients (43.2%) suffering from a recurrent bleeding declared treatment 222 
of a subsequent episode by an ENT specialist. Eleven (11/19=57.9%) patients have 223 
sought an ENT specialist in a private practice and reported following distribution of 224 
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epistaxis treatment: Eight (8) coagulations, one (1) packing, one (1) packing with 225 
subsequent coagulation and one (1) did not reported the performed treatment. 226 
Eight (8/19=42.1%) patients have sought our tertiary ENT emergency and reported 227 
following distribution of epistaxis treatment: Two (2) coagulations, Two (2) packings, 228 
one (1) packing with subsequent coagulation, one (1) packing with subsequent 229 
surgical intervention and two (2) surgical interventions only. 230 
Every single patient (3/3) who had to undergo a surgical intervention in order to stop 231 
a recurrent bleeding stated ASA intake at the initial time point. 232 
 233 
234 
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Discussion: 235 
This cohort survey study is able to show that the intake of a VKA is a significant and 236 
independent long-term risk factor for recurrent epistaxis episodes, while ASA did not 237 
exert a significantly increased risk for recurrent episodes in a long-term perspective. 238 
The exposure to acetylsalicylic acid did however show a link to severe recurrent 239 
nosebleeds, with the need of a more invasive therapeutic revision-intervention. 240 
An extrapolated calculation estimated a prevalence of 15.8% for minor recurrent 241 
epistaxis episodes.4 In our cohort the recurrence rate was very high with more than 242 
every third patient suffering from a recurrent episode. Several potential risk factors 243 
for epistaxis have been identified and discussed controversially for many years. 244 
Some proposed factors maintained their position, and others were either pushed into 245 
the background or were able to gain more attention. 246 
Examples for evaluated risk factors are traumatic injury, physical and chemical 247 
irritation, allergic rhinitis, viral and bacterial rhinosinusitis, nasal tumors, temperature 248 
and humidity or hemostasis impairment. 5,6 Examples for non fully confirmed but 249 
discussed potential risk factors are hypertension7, alcohol consumption8, septal spurs 250 
or deviation.9 251 
A study, conducted to investigate short-time recurrences showed treatment with 252 
untargeted gauze packing due to an unidentified bleeding source as a significant risk 253 
factor for a subsequent bleeding within a one week timeframe.10 On the contrary, did 254 
other concurrently observed risk factors, i.e. patient’s history for rhinitis or sinusitis, 255 
septal deviation, use of antithrombotic agents or history for hypertension show no 256 
significant differences.10 An investigation about the effectiveness of different 257 
treatment options in epistaxis endorsed that coagulation at an anterior and surgical 258 
occlusion at a posterior bleeding are able to successfully salvage failed packing 259 
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therapies.11 Therefore is the appropriate choice of a treatment option of essential 260 
importance in order to reduce recurrences. 261 
Vitamin K antagonist therapy is a long-standing and widely postulated risk factor for 262 
epistaxis.12 A recent, retrospective and controlled cohort study endorses the 263 
suggestions and showed, that besides the exposure to Warfarin®, none of the widely 264 
believed risk factors for epistaxis in general, were associated with risk of recurrence 265 
during a three years period.13 266 
This is in accordance with our finding of Marcoumar®, a Europe-wide used VKA, as 267 
an independent long-term risk factor for recurrent epistaxis episodes. Exposure to 268 
VKA, especially if not regularly checked by a physician, can easily lead to INR levels 269 
that are too high. In order to take appropriate action in case of a nosebleed in 270 
patients who are not within optimal target value ranges, it is recommended to test the 271 
prothrombin time and INR in every epistaxis patient on VKAs.14 272 
The intake of acetylsalicylic acid has recently been added to the group of risk factors. 273 
Although already proposed as a risk factor in the last millennium15, it has unjustly 274 
been pushed into the background by the VKA. Recently, it has been reasserted that 275 
antiaggregational therapy with ASA is not only a subsidiary but a major risk factor for 276 
epistaxis and a higher severity.3 In the same study, did the exposure to ASA 277 
supersede VKA therapy as a risk factor for severe epistaxis.  278 
To the best of our knowledge does the current literature not address the long-term 279 
course of epistaxis patients during a timeframe of more than three years as done in 280 
our investigation. 281 
The exposure to VKA compared to other antithrombotic agents and potential risk 282 
factors shows an odds ratio of 11.6 for recurrences. We also could support the 283 
finding of exposure to ASA as a risk factor for epistaxis episodes with high severity 284 
not only in a short- but also in a long-term perspective. Therefore, for patients with 285 
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exposure to ASA an increased probability for a surgical intervention in order to stop a 286 
recurrent bleeding can be predicted. This finding is not statistically significant due to 287 
its small number of cases. Nonetheless did all patients that required a surgical 288 
intervention in order to stop a recurrent bleeding declare ASA intake at the initial 289 
cohort. 290 
Hypertension as a potential risk factor7 is still controversially discussed and not 291 
confirmed. It was repeatedly described not to increase the risk for epistaxis or its 292 
severity.3,16 Acute hypertension during a nosebleed is a proposed17 and intuitively 293 
apparent cause for a refractory epistaxis. Nevertheless, was acute hypertension 294 
counter-intuitively not a risk factor for severe epistaxis in our own analysis of almost 295 
600 emergency events.3 On the long run, hypertension appears to be a weak 296 
proximate risk factor, as only a (non-significant) trend was observed towards more 297 
recurrences. In addition to hypertension, the covariate male sex also showed an 298 
independent statistical trend for an increased risk for epistaxis. It has been confirmed 299 
that men are at risk for a more extensive coronary disease compared to women.18 300 
These findings support the idea that atherosclerosis, as a consequence of long-term 301 
hypertension and thus continuous stress to the vascular system, leads to more 302 
vulnerable vessels and thus bleeding and recurrences.19  303 
The study is limited due to its non-controlled design and a relatively low response 304 
rate of 35.8% (120/335). However, in such a long postinterventional timeframe and a 305 
relatively old population this was anticipated and therefore a high number of more 306 
than 500 patients in a mean timeframe of 76 months was chosen in order to get the 307 
lowest possible bias. A further potentially limiting factor could be a selection bias. We 308 
consider a selection bias as unlikely, since our cohort was large and there was no 309 
obvious bias concerning the responders and non-responders. 310 
 311 
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In contrast to other studies, we also acquired minor epistaxis episodes, which are 312 
defined as episodes that were handled autonomously by the patient without seeking 313 
help of a general practitioner or an ENT specialist. Therefore, we collected recurrent 314 
episodes regardless of their severity and thus included a cohort that most likely 315 
represents a very representative group of epistaxis patients. Furthermore, the 316 
Hosmer and Lemeshow test indicated a good fit of our logistic regression model.317 
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Conclusion: 318 
Recurrent bleedings after epistaxis treatment are underestimated and occur at a very 319 
high rate. We provide evidence that the intake of a VKA is an independent long-term 320 
risk factor for recurrent epistaxis episodes. 321 
The intake of ASA is a risk factor for the severity of recurrent epistaxis episodes with 322 
the increased need for a surgical intervention not only in a short- but also in a long-323 
term perspective. 324 
Concerning the above mentioned increased risks, we recommend prescribing both 325 
antithrombotic agents only with an indisputable indication. In line with our previous 326 
studies  we imperatively discourage from taking ASA as a “lifestyle drug” at any age. 327 
However, further studies are needed to endorse this recommendation. 328 
Patients with a high-risk profile should be informed and trained in the prevention, 329 
first-aid measures and then seeking medical advice in case of recurrent epistaxis. 330 
Therefore, in order to assess the patients’ risk profile and to provide an accurate 331 
prognosis it is once again crucial to meticulously record the patients’ history. 332 
Matching the patient’s history with evaluated epistaxis risk factors leads to a better 333 
counseling concerning recurrent episodes or their severity.334 
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Table 1  385 
Specific, psychologically elaborated, but not validated, paper-questionnaire 386 
 387 
1. Do you remember the treatment from xxx? 388 
a. No  389 
b. Yes 390 
2. Was surgery in general anesthesia needed at the time? 391 
a. No 392 
b. Yes 393 
3. Were any of the treatments back then painful for you? 394 
a. No 395 
b. Little  396 
c. Medium  397 
d. Strong 398 
e. Very strong 399 
4. Were any of the treatments back then particularly uncomfortable for you? 400 
a. Cautery 401 
b. Packing 402 
c. Surgery 403 
d. None 404 
5. Have you experienced any complications or lasting sequelae during the treatment or later on? 405 
a. No 406 
b. Nasal obstruction 407 
c. Crusting 408 
d. Other: 409 
6. Do you suffer from permanent sequelae after the treatment? 410 
a. No 411 
b. Yes: 412 
7. Have you experienced nose bleeding after the treatment? 413 
a. No 414 
b. Yes, which side?  415 
c. How many times a year? 416 
8. Did you need medical treatment after the initial event? 417 
a. No 418 
b. Yes 419 
c. When? 420 
d. Where? 421 
9. What was done? 422 
a. Cautery 423 
b. Packing 424 
c. Surgery 425 
10. Do you take anticoagulant medication? 426 
a. No 427 
b. Aspirin 428 
c. Marcoumar® (Phenprocoumon) 429 
d. Plavix® (Clopidogrel) 430 
e. Other: 431 
11. Do you have a high blood pressure? 432 
a. No 433 
b. Yes 434 
12. Do you take any medication because of your blood pressure? 435 
a. No 436 
b. Yes 437 
13. Do you have an elevated blood glucose level (Diabetes)? 438 
a. No 439 
b. Yes 440 
14. Are you treated because of your blood glucose (Diabetes)? 441 
a. No 442 
b. Yes 443 
15. In case of recurrent nosebleed, would you prefer nasal packing without anesthesia or surgery with general anesthesia to stop the 444 
bleeding? 445 
a. Packing without anesthesia 446 
b. Surgery in general anesthesia 447 
 448 
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Table 2 
Variables stratified by the incidence of a recurrent epistaxis episode. 
Pearson Chi-Square tests with asymptotic two-sided significances 
 
Variables 
Recurrent 
epistaxis 
(n = 44) 
No recurrent 
epistaxis 
(n = 62) p Value 
 VKA (Marcoumar®) 10   2 .002 
ASA 14   26 .290 
Clopidogrel 1   0 .233 
Other antithrombotic medication 1   1 .806 
Sex   .115 
- Male 
- Female 
34   39 
10   23 
 
 
 
  
Mean age at the initial event (SD), years 62.94 (16.02) 63.37 (15.67)  .889 
Patient’s history for hypertension 31   32  .052 
Patient’s history for diabetes 5   4  .371 
   
Abbreviation: SD, standard deviation 
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 449 
Table 3 
Binary Logistic Regression with epistaxis recurrence as dependent variable. 
Covariates p Value OR 
95% CI for OR 
Lower Upper 
 VKA (Marcoumar®) .007 11.587 1.973 68.057 
ASA .607 .780 .304 2.005 
Clopidogrel 1.000 >10 .000 . 
Other antithrombotic medication .682 1.856 .096 35.717 
Sex .072 2.549 .919 7.068 
Age at the initial event .247 .982 .952 1.013 
Patient’s history for hypertension .086 2.397 .884 6.500 
Patient’s history for diabetes .373 2.062 .419 10.146 
     
Abbreviations: CI, confidential interval; OR, odds ratio 
 450 
451 
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Figure legends: 452 
 453 
Figure 1: Shift of ASA (Acetylsalicylic Acid) and VKA (vitamin K antagonist) intake 454 
between the initial cohort and the survey cohort; y-axis: 0 to 100 patients. 455 
 456 
